$24.94 0.93 (+3.87%)
12/4/2009 10:47 AM

Acorda Therapeutics, Inc. (ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Featured Broker Partners